Cardiovascular Calcification Overview

Cardiovascular Calcification is a process in which mineral deposits formed in vessel walls and heart valve leaflets can lead to tissue stiffening, plaque rupture and heart failure. Several biological processes contribute to cardiovascular calcification, including extracellular vesicle release, matrix remodeling, loss of mineral-deposition inhibition, impaired mineral resorption, oxidative stress, mitochondrial dysfunction, inflammation and stem and progenitor cell programmes.

“Cardiovascular Calcification Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cardiovascular Calcification Market.

The Cardiovascular Calcification Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cardiovascular Calcification Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cardiovascular Calcification treatment therapies with a considerable amount of success over the years. Cardiovascular Calcification Key players such as – Inositec, Sanofi, Abcentra, Dong-A ST, Sanifit, and others, are developing therapies for the Cardiovascular Calcification treatment 

• Cardiovascular Calcification Emerging therapies such as – INS 3001, HMR1766, Orticumab, Evogliptin, SNF472, and others are expected to have a significant impact on the Cardiovascular Calcification market in the coming years.   
• placebo-controlled Phase 3 clinical trial will examine the efficacy and safety of SNF472 in patients who have ulcerated calciphylaxis lesions. Patient recruitment is ongoing and the trial is expected to be completed by April 2022
• In February 2020, Sanifit Therapeutics S. A. initiated a Phase 3, Randomized, DoubleBlind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis

Route of Administration

Cardiovascular Calcification pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type 

Cardiovascular Calcification Pipeline Therapeutics Assessment

• Cardiovascular Calcification Assessment by Product Type
• Cardiovascular Calcification By Stage and Product Type
• Cardiovascular Calcification Assessment by Route of Administration
• Cardiovascular Calcification By Stage and Route of Administration
• Cardiovascular Calcification Assessment by Molecule Type
• Cardiovascular Calcification by Stage and Molecule Type

DelveInsight’s Cardiovascular Calcification Report covers around 6+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Cardiovascular Calcification Therapeutics Market include:

Key companies developing therapies for Cardiovascular Calcification are – Amgen Inc., Novartis AG, Sanofi SA, GlaxoSmithKline, AstraZeneca PLC, Merck & Co., Inc., Eli Lilly and Company, Johnson & Johnson, Pfizer Inc., Boehringer Ingelheim, and others.

Emerging Cardiovascular Calcification Drugs Under Different Phases of Clinical Development Include:

• INS 3001: Inositec
• HMR1766: Sanofi
• INS-3001: Inositec
• Orticumab: Abcentra
• Evogliptin: Dong-A ST
• SNF472: Sanifit

Get a Free Sample PDF Report to know more about Cardiovascular Calcification Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/cardiovascular-calcification-pipeline-insight

Cardiovascular Calcification Pipeline Analysis:

The Cardiovascular Calcification pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Cardiovascular Calcification with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cardiovascular Calcification Treatment.
• Cardiovascular Calcification key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cardiovascular Calcification Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cardiovascular Calcification market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Cardiovascular Calcification product details are provided in the report. Download the Cardiovascular Calcification pipeline report to learn more about the emerging Cardiovascular Calcification therapies

Cardiovascular Calcification Pipeline Market Drivers

• Advances in imaging techniques used to diagnose cardiovascular calcification
• Advances in computational tools that can help to identify novel target to treat cardiovascular calcification

Cardiovascular Calcification Pipeline Market Barriers

• Lack of approved therapies and only a few ongoing clinical trials
• Pathogenesis of the disease in not completely understood

Scope of Cardiovascular Calcification Pipeline Drug Insight    

• Coverage: Global
• Key Cardiovascular Calcification Companies: Inositec, Sanofi, Abcentra, Dong-A ST, Sanifit, and others
• Key Cardiovascular Calcification Therapies: INS 3001, HMR1766, Orticumab, Evogliptin, SNF472, and others
• Cardiovascular Calcification Therapeutic Assessment: Cardiovascular Calcification current marketed and Cardiovascular Calcification emerging therapies
• Cardiovascular Calcification Market Dynamics: Cardiovascular Calcification market drivers and Cardiovascular Calcification market barriers 

Request for Sample PDF Report for Cardiovascular Calcification Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Cardiovascular Calcification drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting